Claim OwnershipThe Uromigos
Subscribed: 54Played: 4,508
Subscribe
© The Uromigos
Description
Broadcasting the latest developments in GU cancer
Hosted by Brian Rini and Tom Powles
Brian Rini MD is a Professor of Cancer Research and Professor of Medicine (Hematology/Oncology), Vanderbilt-Ingram Cancer Center
Tom Powles is the Director of Barts Cancer Centre, St Bartholomew's Hospital and Professor of Genitourinary Oncology, Queen Mary University of London
Hosted by Brian Rini and Tom Powles
Brian Rini MD is a Professor of Cancer Research and Professor of Medicine (Hematology/Oncology), Vanderbilt-Ingram Cancer Center
Tom Powles is the Director of Barts Cancer Centre, St Bartholomew's Hospital and Professor of Genitourinary Oncology, Queen Mary University of London
450 Episodes
Reverse
1Jonathan Rosenberg and a surprise guest discuss comorbidities and treatment-related side effects.
David Braun divides immune therapies into four groups and describes how novel treatments and targets work. Tom and Brian are both excited and, at times, sceptical.
Escuche nuestro primer podcast sobre los aspectos más destacados de ASCO en cáncer de vejiga, riñón y próstata
Axel Bex, Christian Blank, Laura Mertens and Micheil Van der Heijden answer a range of relevant and sometimes irrelevant questions
Viktor Gruenwald, Boris Hadaschik and Gunhild Von Amsberg answer questions around GU cancer and German football
Aditya Bagrodia describes three new drugs/studies in NMIBC.
Silke Gillessen joins Tom and Brian, who give their opinion on the data and new 'Take Home Message' format.
Nobuaki Matsubara, Hiroshi Kitamura and Yuji Miura battle through the sometimes ridiculous questions set by Tom and Brian.
David McDermott discusses the adjuvant vs neoadjuvant immune therapy trial and its wider implications.
Guru Sonpavde describes the efficacy of chemotherapy with nivolumab in lymph node only 1st line UC patients. Tom describes the QOL data for EV pembro.
Laurence Albiges discusses this circulating biomarker which may be predictive and prognostic.
Toni Choueiri and Brian describe similarities and differences in the biomarker findings of these two trials. Debate about the value and future of this approach breaks out.
Andrea Necchi gives us the lowdown of efficacy and toxicity of this combination.
Jonathan Rosenberg gets to grips with the data available for the bladder cohort from the TDXD Destiny pan-tumour cohort.
Alex Wyatt describes the predictive resistance of ctDNA fraction at baseline in predicting outcome.
Christos Kyriakopoulos describes the outcome of this study, where cabazitaxel with abiraterone as combined with abiraterone alone in docetaxel refractory CRPC.
Danny Heng, Christian Kollmannsberger and Kala Sridhar answer questions in an attempt to get to Nashville and take on LA to win the Uromigos Cup.
What to see at the ASCO 2024 Annual Meeting, with Silke Gillessen.
Nick James discusses this paper, which covers broad issues in prostate cancer - including diagnosis and treatment with a focus on the future.
David Penson discusses highlights for the upcoming meeting. He articulates his excitement around the NMIBC data.
Comments
Download from Google Play
Download from App Store
United States